ArticleAnalytical chemistry2018
Microfluidic Low-Input Fluidized-Bed Enabled ChIP-seq Device for Automated and Parallel Analysis of Histone Modifications.
Article in Analytical chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Lossless Altered Histone Modification Analysis System (LAHMAS).Lab on a chip · 2025Article
- High-throughput extraction on a dynamic solid phase for low-abundance biomarker isolation from biological samples.Microsystems & nanoengineering · 2023Article
- Modular microfluidic system for on-chip extraction, preconcentration and detection of the cytokine biomarker IL-6 in biofluid.Scientific reports · 2022Article
- nMOWChIP-seq: low-input genome-wide mapping of non-histone targets.NAR genomics and bioinformatics · 2022Article
- Joint single-cell multiomic analysis in Wnt3a induced asymmetric stem cell division.Nature communications · 2021Article
- A plug and play microfluidic platform for standardized sensitive low-input chromatin immunoprecipitation.Genome research · 2021Article
- Multiplexed and Ultralow-Input ChIP-seq Enabled by Tagmentation-Based Indexing and Facile Microfluidics.Analytical chemistry · 2020Article
- Translational Opportunities for Microfluidic Technologies to Enable Precision Epigenomics.Analytical chemistry · 2020Article
- Microfluidic Platform for Next-Generation Sequencing Library Preparation with Low-Input Samples.Analytical chemistry · 2020Article
- Perspectives on the Role of Histone Modification in Breast Cancer Progression and the Advanced Technological Tools to Study Epigenetic Determinants of Metastasis.Frontiers in genetics · 2020Review
- Microfluidic epigenomic mapping technologies for precision medicine.Lab on a chip · 2019Review
- A diffusion-based microfluidic device for single-cell RNA-seq.Lab on a chip · 2019Article
- Engineered microscale hydrogels for drug delivery, cell therapy, and sequencing.Biomedical microdevices · 2019Review
- On-chip manufacturing of synthetic proteins for point-of-care therapeutics.Microsystems & nanoengineering · 2019Article
- A droplet microfluidic platform for efficient enzymatic chromatin digestion enables robust determination of nucleosome positioning.Lab on a chip · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Genome-wide epigenetic changes, such as histone modifications, form a critical layer of gene regulations and have been implicated in a number of different disorders such as cancer and inflammation. Progress has been made to decrease the input required by gold-standard genome-wide profiling tools like chromatin immunoprecipitation followed by sequencing (i.e., ChIP-seq) to allow scarce primary tissues of a specific type from patients and lab animals to be tested. However, there has been practically no effort to rapidly increase the throughput of these low-input tools. In this report, we demonstrate LIFE-ChIP-seq (low-input fluidized-bed enabled chromatin immunoprecipitation followed by sequencing), an automated and high-throughput microfluidic platform capable of running multiple sets of ChIP assays on multiple histone marks in as little as 1 h with as few as 50 cells per assay. Our technology will enable testing of a large number of samples and replicates with low-abundance primary samples in the context of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.